Antiviral agents will lead encephalitis treatment sales through 2036 with 36.9% of the treatment segment in 2026. The market was valued at USD 22.37 billion in 2025 and is expected to reach USD 37.9 billion by 2036, creating an incremental opportunity of USD 14.40 billion between 2026 and 2036.